4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001992260-26-000004
EVP, Head of R&D sold 33,830 shares at $81.48 ($2,756,468)
- EVP, Head of R&D acquired 33,830 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Option exercise 10b5-1 | +7,998 | $8.44 | $67,503 | 7,998 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Option exercise 10b5-1 | +5,000 | $17.88 | $89,400 | 12,998 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Option exercise 10b5-1 | +8,332 | $21.77 | $181,388 | 21,330 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Option exercise 10b5-1 | +12,500 | $22.07 | $275,875 | 33,830 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Sale 10b5-1 | −33,830 | $81.48 | $2,756,468 | 0 | D |
| Derivatives | |||||||
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,998 | 3,998 | D | ||
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 71,184 | D | ||
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,332 | 54,174 | D | ||
| Randhawa Simrat EVP, Head of R&D | 2026-03-12 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,500 | 106,250 | D | ||
| Open-market sales · 33,830 sh · avg $81.48 · $2,756,468 | |||||||
Loading xslF345X05/ownership.xml…